Spiliotis J, Argiriou E O, Vafias E, Manou V, Vaos N, Datsis A, Efstathiou E
a 1st Department of Surgical Oncology , Metaxa Cancer Hospital , Piraeus , Greece ;
b ICU , Metaxa Cancer Hospital , Piraeus , Greece ;
Acta Chir Belg. 2016 Apr;116(2):96-100. doi: 10.1080/00015458.2016.1165019.
Peritoneal metastasis (PM) is currently treated with the complex procedure of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (CRS + HIPEC). This procedure presents high morbidity and mortality rates, but they have only been examined in the immediate post-operative period. The aim of our study is to present, describe and analyze the post-operative events, secondary to a cytoreductive surgery and HIPEC procedure that occurs after the patients' discharge from the hospital.
We examine retrospectively 219 patients who were discharged from our hospital from the initial 230 patients with PM, who were operated on from August 2005 to August 2015 and underwent CRS and HIPEC. Complications are investigated from the patient's discharge date until the 90th post-operative day, and are categorized with the Clavien-Dindo classification.
We identified 17 patients (7.8%) who developed late complications. No major differences in patient characteristics were identified between this group of 17 patients and the rest, apart from a slightly higher PCI (23.5 vs. 22.3). Mean length of stay at the re-admission was 11.7 days. 5 of the patients (29.4%) had to be re-operated on, whereas we found a mortality of 11.8% (2/17 patients). The most common complications involved abdominal abscesses (17.6%), ureteral strictures (17.6%) and enterocutaneous fistulae (17.6%).
Our study highlights the late complications following CRS plus HIPEC procedures, that occur after the patient's discharge from the hospital, an issue that has not been investigated thoroughly yet and may have serious impact on the post-operative quality of life. The role of adjuvant chemotherapy following CRS and HIPEC procedures in the onset of such complications appears to be important and needs further investigation.
目前,腹膜转移(PM)采用细胞减灭术和腹腔内热灌注化疗(CRS+HIPEC)这一复杂手术进行治疗。该手术具有较高的发病率和死亡率,但此前仅在术后即刻进行过评估。我们研究的目的是呈现、描述和分析患者出院后因细胞减灭术和HIPEC手术引发的术后事件。
我们回顾性研究了我院自2005年8月至2015年8月期间接受手术并进行CRS和HIPEC的230例PM患者中的219例出院患者。从患者出院日期至术后第90天对并发症进行调查,并根据Clavien-Dindo分类法进行分类。
我们发现17例患者(7.8%)出现了晚期并发症。除了PCI略高(23.5对22.3)外,这17例患者与其余患者在患者特征方面未发现重大差异。再次入院后的平均住院时间为11.7天。5例患者(29.4%)需要再次手术,而我们发现死亡率为11.8%(2/17例患者)。最常见的并发症包括腹腔脓肿(17.6%)、输尿管狭窄(17.6%)和肠皮肤瘘(17.6%)。
我们的研究突出了CRS加HIPEC手术后患者出院后出现的晚期并发症,这一问题尚未得到充分研究,可能会对术后生活质量产生严重影响。CRS和HIPEC手术后辅助化疗在这些并发症发生中的作用似乎很重要,需要进一步研究。